These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 37180989)
1. Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer's disease? Saura CA; Parra-Damas A Brain Commun; 2023; 5(3):fcad142. PubMed ID: 37180989 [TBL] [Abstract][Full Text] [Related]
2. Distinct brain pathologies associated with Alzheimer's disease biomarker-related phospho-tau 181 and phospho-tau 217 in Hirota Y; Sakakibara Y; Ibaraki K; Takei K; Iijima KM; Sekiya M Brain Commun; 2022; 4(6):fcac286. PubMed ID: 36440096 [TBL] [Abstract][Full Text] [Related]
3. Cognitive resilience in Alzheimer's disease: from large-scale brain networks to synapses. Negro D; Opazo P Brain Commun; 2024; 6(1):fcae050. PubMed ID: 38425748 [TBL] [Abstract][Full Text] [Related]
4. In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease. Toombs J; Zetterberg H Brain Commun; 2020; 2(1):fcaa054. PubMed ID: 32954304 [TBL] [Abstract][Full Text] [Related]
6. Early and specific detection of Alzheimer's disease: more than a (virtual) reality? Almeida OFX Brain Commun; 2024; 6(1):fcae014. PubMed ID: 38347943 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Alzheimer's disease: how to predict who will decline next year? Hanseeuw BJ; Johnson KA Brain Commun; 2023; 5(2):fcad079. PubMed ID: 37006330 [TBL] [Abstract][Full Text] [Related]
8. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
9. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M; Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949 [TBL] [Abstract][Full Text] [Related]
10. Candesartan-the next anti-amyloid drug? Yasar S Brain Commun; 2022; 4(6):fcac293. PubMed ID: 36440098 [TBL] [Abstract][Full Text] [Related]
11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
14. Eigenvector centrality and its variability over time are promising indicators of alterations in brain function due to early amyloid deposition. Skouras S Brain Commun; 2023; 5(3):fcad104. PubMed ID: 37151224 [TBL] [Abstract][Full Text] [Related]
15. The Teflon hypothesis. Castellani RJ; Perry G Brain Commun; 2023; 5(4):fcad203. PubMed ID: 37492487 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663 [TBL] [Abstract][Full Text] [Related]
18. Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias? Newby D Brain Commun; 2022; 4(5):fcac260. PubMed ID: 36324868 [TBL] [Abstract][Full Text] [Related]
19. Neurophysiological effects of human-derived pathological tau conformers in the APPKM670/671NL.PS1/L166P amyloid mouse model of Alzheimer's disease. Tok S; Maurin H; Delay C; Crauwels D; Manyakov NV; Van Der Elst W; Moechars D; Drinkenburg WHIM Sci Rep; 2022 May; 12(1):7784. PubMed ID: 35546164 [TBL] [Abstract][Full Text] [Related]